Related Experiment Video
Updated: May 17, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel
Caterina Mecca1, Agostino Ponzetti, Virginia Caliendo
1Medical Oncology 1 Division, San Giovanni Battista Hospital, Corso Bramante 88,Turin, Italy. caterinamecca@yahoo.it
Background And Methods:
Cetuximab therapy results strongly active in advanced cutaneous squamous cell carcinoma (cSCC). A patient affected by a rapidly progressing, already irradiated and cisplatin-refractory cSCC, with lung, pleura and thoracic lymph nodes metastasis, was treated with weekly cetuximab and paclitaxel.
Results:
Treatment was well tolerated and a partial response was obtained after four months of cetuximab plus paclitaxel therapy. Then we continued maintenance cetuximab for another seven months with tumor shrinkage until complete response, maintained after six months.
Conclusions:
Cetuximab was safely associated with paclitaxel, obtaining a rapid tumor response in cisplatin-refractory metastatic cSCC. Single-agent cetuximab maintenance sustained tumor shrinkage until complete response.